

ENSAYOS CLÍNICOS TUMORES DIGESTIVO

- COLORRECTAL

SMS-0472B

"A randomized, multicentre, open-label controlled phase II trial of Foxy-5 as neo-adjuvant therapy in subjects with Wnt-5a negative colon cancer"

<https://clinicaltrials.gov/ct2/show/NCT03883802>

BNT 122-01

"A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection."

<https://clinicaltrials.gov/ct2/show/NCT04486378>

C4221015 (BREAKWATER)

"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER"

<https://clinicaltrials.gov/ct2/show/NCT04607421>

C4221022 (SEAMARK)

"A phase 2, randomized, open-label study of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSIH/DMMR metastatic colorectal cancer"

<https://clinicaltrials.gov/ct2/show/NCT05217446>

NUTIDE:323

"A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated unresectable metastatic colorectal cancer"

<https://clinicaltrials.gov/ct2/show/NCT05678257>

849-010

"A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy"

<https://clinicaltrials.gov/ct2/show/NCT04793958>

MK1308A-008

“A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK3475) or MK- 1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)”

<https://clinicaltrials.gov/ct2/show/NCT04895722>

61186372GIC2002

“A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer”

<https://clinicaltrials.gov/ct2/show/NCT05379595>

219369

“A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer”

<https://clinicaltrials.gov/ct2/show/NCT05723562>

- GÁSTRICO

FORTITUDE -101 (20210096)

“A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101)”

<https://clinicaltrials.gov/ct2/show/NCT05052801>

DS8201-A-U306

“A PHASE 3, MULTICENTER, 2-ARM RANDOMIZED, OPEN-LABEL STUDY OF TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH HER2-POSITIVE METASTATIC AND/OR UNRESECTABLE GASTRIC OR GASTRO-ESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PROGRESSED ON OR AFTER A TRASTUZUMAB-CONTAINING REGIMEN (DESTINY-GASTRIC04)”

<https://clinicaltrials.gov/ct2/show/NCT04704934>

- ESÓGAFO

MK7902-014

"A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma"

<https://clinicaltrials.gov/ct2/show/NCT04949256>

- VIA BILIAR

INCB 54828-302

"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement".

<https://clinicaltrials.gov/ct2/show/NCT03656536>

- PÁNCREAS

CCL-SBP-101-04

"A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma"

<https://clinicaltrials.gov/ct2/show/NCT05254171>

ABT-C11-2020

"A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer"

<https://clinicaltrials.gov/ct2/show/NCT04431258>

TRIPP-FFX

"An open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 (OncoSi™) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma"

<https://clinicaltrials.gov/ct2/show/NCT05466799>

P-VCNA-003

"A Phase IIb, Open-label, Randomized Study of NabPaclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)"

<https://clinicaltrials.gov/ct2/show/NCT05673811>

TTD-20-04

"Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations"

<https://clinicaltrials.gov/ct2/show/NCT05659914>

TROMBOSIS

ANT-007 (ASTER)

"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE"

<https://clinicaltrials.gov/ct2/show/NCT05171049>

ANT-008 (MAGNOLIA)

"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE"

<https://clinicaltrials.gov/ct2/show/NCT05171075>

NEUROPATIA

ATX01-22-01-CIPN

"A multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in comparison to placebo, in cancer survivor adult patients with chemotherapy-induced peripheral neuropathy (CIPN)"

<https://clinicaltrials.gov/ct2/show/NCT05593614>

CINV (Naúseas/Vómitos)

MYRISK

"Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study".

<https://clinicaltrials.gov/ct2/show/NCT04817189>